{"id":26240,"date":"2026-03-16T10:53:31","date_gmt":"2026-03-16T08:53:31","guid":{"rendered":"https:\/\/makingpharmaindustry.it\/non-categorizzato\/one-health-e-amr-la-nuova-agenda-globale\/"},"modified":"2026-03-25T14:04:35","modified_gmt":"2026-03-25T12:04:35","slug":"one-health-e-amr-la-nuova-agenda-globale","status":"publish","type":"post","link":"https:\/\/makingpharmaindustry.it\/en\/one-health-en\/one-health-e-amr-la-nuova-agenda-globale\/","title":{"rendered":"One Health and AMR: the new global agenda"},"content":{"rendered":"<p data-start=\"0\" data-end=\"246\">Antimicrobial resistance is no longer just a clinical or scientific challenge. It has increasingly become an issue of <strong>global health governance<\/strong>, with the power to influence industrial policies, pharmaceutical regulation, and investment strategies.<\/p>\n<p data-start=\"248\" data-end=\"475\">A significant step in this direction is represented by the <strong><em data-start=\"307\" data-end=\"379\">Draft Updated Global Action Plan on Antimicrobial Resistance 2026\u20132036<\/em><\/strong>, presented by the <span class=\"hover:entity-accent entity-underline inline cursor-pointer align-baseline\"><span class=\"whitespace-normal\">World Health Organization<\/span><\/span> to its Executive Board in January 2026.<\/p>\n<p data-start=\"477\" data-end=\"629\" data-is-last-node=\"\" data-is-only-node=\"\">The document updates the first global plan adopted in 2015 and introduces a broader strategic framework, explicitly grounded in the <strong>One Health approach<\/strong>.<\/p>\n<h2 data-start=\"0\" data-end=\"56\">From the 2015 plan to a broader governance framework<\/h2>\n<p data-start=\"58\" data-end=\"313\">The 2015 WHO plan defined five main objectives: improving awareness of antimicrobial resistance (AMR), strengthening surveillance, reducing the incidence of infections, optimizing the use of antimicrobials, and supporting the development of new therapies.<\/p>\n<p data-start=\"315\" data-end=\"526\">The <strong>new 2026\u20132036 draft<\/strong> expands this vision. Antimicrobial resistance is framed as a systemic challenge involving public health, agriculture, the environment, the pharmaceutical industry, and regulatory systems.<\/p>\n<p data-start=\"528\" data-end=\"707\">The plan puts forward a \u201c<strong>whole-of-society<\/strong>\u201d governance model, calling for coordinated action among governments, international organizations, industry, and the scientific community.<\/p>\n<h2 data-start=\"714\" data-end=\"759\">Antibiotic innovation and economic models<\/h2>\n<p data-start=\"761\" data-end=\"940\">One of the most critical issues concerns therapeutic innovation. Despite growing clinical need, the development of new antibiotics continues to face <strong>significant economic barriers<\/strong>.<\/p>\n<p data-start=\"942\" data-end=\"1037\">The WHO plan explicitly acknowledges the need for new incentive models for research, including:<\/p>\n<ul data-start=\"1039\" data-end=\"1186\">\n<li data-section-id=\"9k2ghz\" data-start=\"1039\" data-end=\"1073\">market entry reward mechanisms<\/li>\n<li data-section-id=\"dnpuew\" data-start=\"1074\" data-end=\"1120\">public\u2013private funds for antimicrobial R&amp;D<\/li>\n<li data-section-id=\"17p2704\" data-start=\"1121\" data-end=\"1186\">payment models that decouple clinical value from sales volume<\/li>\n<\/ul>\n<p data-start=\"1188\" data-end=\"1400\" data-is-last-node=\"\" data-is-only-node=\"\">These tools are designed to address a well-known paradox in the field: antibiotics must be used sparingly to prevent resistance, but this very restraint undermines the economic incentive to develop new molecules.<\/p>\n<h2 data-start=\"0\" data-end=\"33\">Global access and stewardship<\/h2>\n<p data-start=\"35\" data-end=\"333\">The new plan also reinforces the issue of access to medicines. The <span class=\"hover:entity-accent entity-underline inline cursor-pointer align-baseline\"><span class=\"whitespace-normal\">World Health Organization<\/span><\/span> emphasizes that tackling AMR requires a balance between <strong>ensuring access to essential antimicrobials<\/strong> in low-income countries and promoting <strong>responsible use<\/strong> to prevent the emergence of resistance.<\/p>\n<p data-start=\"335\" data-end=\"623\">For the industry, this implies an increasingly active role in stewardship programs and responsible distribution models. Pharmaceutical companies are now expected to demonstrate not only the scientific quality of their products, but also the <strong>sustainability of their use over the long term<\/strong>.<\/p>\n<h2 data-start=\"630\" data-end=\"666\">The European and Italian context<\/h2>\n<p data-start=\"668\" data-end=\"928\">The global strategy is also reflected in European and national policies. In Italy, the <strong>address act issued by the <span class=\"hover:entity-accent entity-underline inline cursor-pointer align-baseline\"><span class=\"whitespace-normal\">Ministero della Salute<\/span><\/span> for 2026<\/strong> reiterates the commitment to tackling antimicrobial resistance according to the One Health approach.<\/p>\n<p data-start=\"930\" data-end=\"1077\">The <strong><span class=\"hover:entity-accent entity-underline inline cursor-pointer align-baseline\"><span class=\"whitespace-normal\">Piano Nazionale di Contrasto dell\u2019Antimicrobico-Resistenza (PNCAR) 2022-2025<\/span><\/span><\/strong> has been extended until 2026, while a new programming cycle for 2027\u20132031 is currently under development.<\/p>\n<p data-start=\"1079\" data-end=\"1284\" data-is-last-node=\"\" data-is-only-node=\"\">This means that in the coming years AMR will continue to be a priority for both Italian and European health policies, with potential implications for pharmaceutical regulation and public research programs.<\/p>\n<h2 data-start=\"0\" data-end=\"54\">A new responsibility for the pharmaceutical sector<\/h2>\n<p data-start=\"56\" data-end=\"243\">The <strong>growing centrality of antimicrobial resistance<\/strong> in global policy agendas suggests that the role of the pharmaceutical industry can no longer be limited to the development of new drugs.<\/p>\n<p data-start=\"245\" data-end=\"529\">Research, sustainable manufacturing, global access, and stewardship will increasingly become integrated components of industrial strategy. In other words, the One Health approach is progressively reshaping the relationship between the pharmaceutical industry and global public health.<\/p>\n<p data-start=\"531\" data-end=\"744\" data-is-last-node=\"\" data-is-only-node=\"\">For companies operating in the sector, anticipating these transformations may represent not only a public health responsibility, but also a competitive advantage in the emerging international regulatory landscape.<\/p>\n<h3 data-section-id=\"x8y03j\" data-start=\"12015\" data-end=\"12023\">Resources<\/h3>\n<p data-start=\"12025\" data-end=\"12190\">World Health Organization. <em data-start=\"12052\" data-end=\"12124\">Draft updated Global Action Plan on Antimicrobial Resistance 2026\u20132036<\/em>.<br data-start=\"12125\" data-end=\"12128\" \/><a class=\"decorated-link\" href=\"https:\/\/apps.who.int\/gb\/ebwha\/pdf_files\/EB158\/B158_18-en.pdf\" target=\"_new\" rel=\"noopener\" data-start=\"12128\" data-end=\"12188\">https:\/\/apps.who.int\/gb\/ebwha\/pdf_files\/EB158\/B158_18-en.pdf<\/a><\/p>\n<p data-start=\"12192\" data-end=\"12353\">Ministero della Salute. <em data-start=\"12216\" data-end=\"12240\">Atto di indirizzo 2026<\/em>.<br data-start=\"12241\" data-end=\"12244\" \/><a class=\"decorated-link\" href=\"https:\/\/www.salute.gov.it\/new\/sites\/default\/files\/2026-01\/Atto%20di%20indirizzo%202026_firmato%20Ministro.pdf\" target=\"_new\" rel=\"noopener\" data-start=\"12244\" data-end=\"12353\">https:\/\/www.salute.gov.it\/new\/sites\/default\/files\/2026-01\/Atto%20di%20indirizzo%202026_firmato%20Ministro.pdf<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The WHO draft Global Action Plan 2026\u20132036 reinforces the One Health approach to antimicrobial resistance. Between global governance, equitable access, and incentives for antibiotic innovation, the new health agenda is set to have direct implications for pharmaceutical industry strategies.<\/p>\n","protected":false},"author":32,"featured_media":26176,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[807,1103],"tags":[],"class_list":{"0":"post-26240","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-one-health-en","8":"category-sanita-en"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>One Health and AMR: the new global agenda - MakingPharmaIndustry<\/title>\n<meta name=\"description\" content=\"Global Action Plan dell\u2019OMS e politiche europee: la lotta all\u2019AMR \u00e8 una priorit\u00e0 strutturale della governance sanitaria globale\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/makingpharmaindustry.it\/en\/one-health-en\/one-health-e-amr-la-nuova-agenda-globale\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"One Health and AMR: the new global agenda - MakingPharmaIndustry\" \/>\n<meta property=\"og:description\" content=\"Global Action Plan dell\u2019OMS e politiche europee: la lotta all\u2019AMR \u00e8 una priorit\u00e0 strutturale della governance sanitaria globale\" \/>\n<meta property=\"og:url\" content=\"https:\/\/makingpharmaindustry.it\/en\/one-health-en\/one-health-e-amr-la-nuova-agenda-globale\/\" \/>\n<meta property=\"og:site_name\" content=\"MakingPharmaIndustry\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-16T08:53:31+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-25T12:04:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2026\/03\/ChatGPT-Image-12-mar-2026-16_44_31-1024x683.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"683\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Valentina Parrella\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Valentina Parrella\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/one-health-en\/one-health-e-amr-la-nuova-agenda-globale\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/one-health-en\/one-health-e-amr-la-nuova-agenda-globale\/\"},\"author\":{\"name\":\"Valentina Parrella\",\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/#\/schema\/person\/a17e8d1b62d20f6ded5c1564729ba42b\"},\"headline\":\"One Health and AMR: the new global agenda\",\"datePublished\":\"2026-03-16T08:53:31+00:00\",\"dateModified\":\"2026-03-25T12:04:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/one-health-en\/one-health-e-amr-la-nuova-agenda-globale\/\"},\"wordCount\":603,\"image\":{\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/one-health-en\/one-health-e-amr-la-nuova-agenda-globale\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2026\/03\/ChatGPT-Image-12-mar-2026-16_44_31.png\",\"articleSection\":[\"ONE HEALTH\",\"Sanit\u00e0\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/one-health-en\/one-health-e-amr-la-nuova-agenda-globale\/\",\"url\":\"https:\/\/makingpharmaindustry.it\/en\/one-health-en\/one-health-e-amr-la-nuova-agenda-globale\/\",\"name\":\"One Health and AMR: the new global agenda - MakingPharmaIndustry\",\"isPartOf\":{\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/one-health-en\/one-health-e-amr-la-nuova-agenda-globale\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/one-health-en\/one-health-e-amr-la-nuova-agenda-globale\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2026\/03\/ChatGPT-Image-12-mar-2026-16_44_31.png\",\"datePublished\":\"2026-03-16T08:53:31+00:00\",\"dateModified\":\"2026-03-25T12:04:35+00:00\",\"author\":{\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/#\/schema\/person\/a17e8d1b62d20f6ded5c1564729ba42b\"},\"description\":\"Global Action Plan dell\u2019OMS e politiche europee: la lotta all\u2019AMR \u00e8 una priorit\u00e0 strutturale della governance sanitaria globale\",\"breadcrumb\":{\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/one-health-en\/one-health-e-amr-la-nuova-agenda-globale\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/makingpharmaindustry.it\/en\/one-health-en\/one-health-e-amr-la-nuova-agenda-globale\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/one-health-en\/one-health-e-amr-la-nuova-agenda-globale\/#primaryimage\",\"url\":\"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2026\/03\/ChatGPT-Image-12-mar-2026-16_44_31.png\",\"contentUrl\":\"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2026\/03\/ChatGPT-Image-12-mar-2026-16_44_31.png\",\"width\":1536,\"height\":1024},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/one-health-en\/one-health-e-amr-la-nuova-agenda-globale\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/makingpharmaindustry.it\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"One Health and AMR: the new global agenda\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/#website\",\"url\":\"https:\/\/makingpharmaindustry.it\/en\/\",\"name\":\"MakingPharmaIndustry\",\"description\":\"Luogo di incontro\u00a0per approfondire e discutere le pi\u00f9 importanti tematiche del mondo Pharma, dalla ricerca e sviluppo al manufacturing, dal mercato al business\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/makingpharmaindustry.it\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/#\/schema\/person\/a17e8d1b62d20f6ded5c1564729ba42b\",\"name\":\"Valentina Parrella\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/9489e527cae2d980412b4296f66093487551a8e1010c544334080d6b66e72eeb?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/9489e527cae2d980412b4296f66093487551a8e1010c544334080d6b66e72eeb?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/9489e527cae2d980412b4296f66093487551a8e1010c544334080d6b66e72eeb?s=96&d=mm&r=g\",\"caption\":\"Valentina Parrella\"},\"url\":\"https:\/\/makingpharmaindustry.it\/en\/author\/valentina-parrella\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"One Health and AMR: the new global agenda - MakingPharmaIndustry","description":"Global Action Plan dell\u2019OMS e politiche europee: la lotta all\u2019AMR \u00e8 una priorit\u00e0 strutturale della governance sanitaria globale","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/makingpharmaindustry.it\/en\/one-health-en\/one-health-e-amr-la-nuova-agenda-globale\/","og_locale":"en_US","og_type":"article","og_title":"One Health and AMR: the new global agenda - MakingPharmaIndustry","og_description":"Global Action Plan dell\u2019OMS e politiche europee: la lotta all\u2019AMR \u00e8 una priorit\u00e0 strutturale della governance sanitaria globale","og_url":"https:\/\/makingpharmaindustry.it\/en\/one-health-en\/one-health-e-amr-la-nuova-agenda-globale\/","og_site_name":"MakingPharmaIndustry","article_published_time":"2026-03-16T08:53:31+00:00","article_modified_time":"2026-03-25T12:04:35+00:00","og_image":[{"width":1024,"height":683,"url":"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2026\/03\/ChatGPT-Image-12-mar-2026-16_44_31-1024x683.png","type":"image\/png"}],"author":"Valentina Parrella","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Valentina Parrella","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/makingpharmaindustry.it\/en\/one-health-en\/one-health-e-amr-la-nuova-agenda-globale\/#article","isPartOf":{"@id":"https:\/\/makingpharmaindustry.it\/en\/one-health-en\/one-health-e-amr-la-nuova-agenda-globale\/"},"author":{"name":"Valentina Parrella","@id":"https:\/\/makingpharmaindustry.it\/en\/#\/schema\/person\/a17e8d1b62d20f6ded5c1564729ba42b"},"headline":"One Health and AMR: the new global agenda","datePublished":"2026-03-16T08:53:31+00:00","dateModified":"2026-03-25T12:04:35+00:00","mainEntityOfPage":{"@id":"https:\/\/makingpharmaindustry.it\/en\/one-health-en\/one-health-e-amr-la-nuova-agenda-globale\/"},"wordCount":603,"image":{"@id":"https:\/\/makingpharmaindustry.it\/en\/one-health-en\/one-health-e-amr-la-nuova-agenda-globale\/#primaryimage"},"thumbnailUrl":"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2026\/03\/ChatGPT-Image-12-mar-2026-16_44_31.png","articleSection":["ONE HEALTH","Sanit\u00e0"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/makingpharmaindustry.it\/en\/one-health-en\/one-health-e-amr-la-nuova-agenda-globale\/","url":"https:\/\/makingpharmaindustry.it\/en\/one-health-en\/one-health-e-amr-la-nuova-agenda-globale\/","name":"One Health and AMR: the new global agenda - MakingPharmaIndustry","isPartOf":{"@id":"https:\/\/makingpharmaindustry.it\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/makingpharmaindustry.it\/en\/one-health-en\/one-health-e-amr-la-nuova-agenda-globale\/#primaryimage"},"image":{"@id":"https:\/\/makingpharmaindustry.it\/en\/one-health-en\/one-health-e-amr-la-nuova-agenda-globale\/#primaryimage"},"thumbnailUrl":"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2026\/03\/ChatGPT-Image-12-mar-2026-16_44_31.png","datePublished":"2026-03-16T08:53:31+00:00","dateModified":"2026-03-25T12:04:35+00:00","author":{"@id":"https:\/\/makingpharmaindustry.it\/en\/#\/schema\/person\/a17e8d1b62d20f6ded5c1564729ba42b"},"description":"Global Action Plan dell\u2019OMS e politiche europee: la lotta all\u2019AMR \u00e8 una priorit\u00e0 strutturale della governance sanitaria globale","breadcrumb":{"@id":"https:\/\/makingpharmaindustry.it\/en\/one-health-en\/one-health-e-amr-la-nuova-agenda-globale\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/makingpharmaindustry.it\/en\/one-health-en\/one-health-e-amr-la-nuova-agenda-globale\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/makingpharmaindustry.it\/en\/one-health-en\/one-health-e-amr-la-nuova-agenda-globale\/#primaryimage","url":"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2026\/03\/ChatGPT-Image-12-mar-2026-16_44_31.png","contentUrl":"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2026\/03\/ChatGPT-Image-12-mar-2026-16_44_31.png","width":1536,"height":1024},{"@type":"BreadcrumbList","@id":"https:\/\/makingpharmaindustry.it\/en\/one-health-en\/one-health-e-amr-la-nuova-agenda-globale\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/makingpharmaindustry.it\/en\/"},{"@type":"ListItem","position":2,"name":"One Health and AMR: the new global agenda"}]},{"@type":"WebSite","@id":"https:\/\/makingpharmaindustry.it\/en\/#website","url":"https:\/\/makingpharmaindustry.it\/en\/","name":"MakingPharmaIndustry","description":"Luogo di incontro\u00a0per approfondire e discutere le pi\u00f9 importanti tematiche del mondo Pharma, dalla ricerca e sviluppo al manufacturing, dal mercato al business","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/makingpharmaindustry.it\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/makingpharmaindustry.it\/en\/#\/schema\/person\/a17e8d1b62d20f6ded5c1564729ba42b","name":"Valentina Parrella","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/9489e527cae2d980412b4296f66093487551a8e1010c544334080d6b66e72eeb?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/9489e527cae2d980412b4296f66093487551a8e1010c544334080d6b66e72eeb?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/9489e527cae2d980412b4296f66093487551a8e1010c544334080d6b66e72eeb?s=96&d=mm&r=g","caption":"Valentina Parrella"},"url":"https:\/\/makingpharmaindustry.it\/en\/author\/valentina-parrella\/"}]}},"_links":{"self":[{"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/posts\/26240","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/users\/32"}],"replies":[{"embeddable":true,"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/comments?post=26240"}],"version-history":[{"count":3,"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/posts\/26240\/revisions"}],"predecessor-version":[{"id":26243,"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/posts\/26240\/revisions\/26243"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/media\/26176"}],"wp:attachment":[{"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/media?parent=26240"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/categories?post=26240"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/tags?post=26240"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}